SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101) (PLSE) — Apr 18, 2016

PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101)
Date: April 18, 2016 · CIK: 0001625101 · Accession: 0000000000-16-072508

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
April 15, 2016
Author
/s/ Amanda Ravitz
Form
UPLOAD
Company
PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101)

Letter

Mail Stop 3030 April 15, 2016 Via E -mail Darrin R. Uecker President and Chief Executive Officer Pulse Biosciences, Inc. 849 Mitten Road, Suite 104 Burlingame, California 94010

Re: Pulse Biosciences, Inc. Amendment No. 2 to Registration Statement on Form S -1 Filed March 28, 2016 File No. 333 -208694

Dear Mr. Uecker :

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our comments apply t o your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have a dditional comments. Unless we note otherwise, our references to prior comments are to comments in our March 21, 2016 letter.

Prospectus Summary, page 1

1. We are unable to agree with your response to prior comment 5 given the tests appear to be in order to pursue regulatory clearance for your system rather than for marketing. Please revise your disclosure to highlight the limited nature of certain of the referenced studies and trials.

Business, page 26

2. Please tell us why you do include in this section disclosure required by Item 101(a) of Regulation S -K regarding your relationship with Electroblate, Inc.

Darrin R. Uecker Pulse Biosciences, Inc. April 15, 2016 Page 2

Exhibit s

3. We are unable to agree with your response to prior comment 13 given the agreement was performed in part after you filed the registration statement on December 22, 2015. File as an exhibit the research and funding agreement mentioned on page 40.

Exhibit 5.1

4. The opinion that you file to satisfy your obligations under Regulation S -K Item 60 1(b)(5) may not assume conclusions of law that are a necessary requirement of the ultimate opinion nor may it assume any of the material facts underlying the opinion or facts that are readily ascertainable. We note the last two sentences of the second para graph of the exhibit that you filed. Please file an opinion that is revised as appropriate.

You may contact David Burton at (202) 551 -3640 or Kevin Kuhar, Accounting Branch Chief, at (202) 551 -3662 if you have questions regarding comments on the financi al statements and related matters. Please contact Tom Jones at (202) 551 -3602 or me at (202) 551 -3528 with any other questions.

Sincerely,
/s/ Amanda Ravitz

Show Raw Text
Mail Stop 3030
        April 15, 2016

Via E -mail
Darrin R. Uecker
President and Chief Executive Officer
Pulse Biosciences, Inc.
849 Mitten Road, Suite 104
Burlingame, California 94010

Re: Pulse Biosciences, Inc.
 Amendment No. 2 to Registration Statement on Form S -1
Filed March 28, 2016
  File No. 333 -208694

Dear Mr. Uecker :

We have reviewed your amended registration statement and have the following
comments.  In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the
requested information .  If you do not believe our comments apply t o your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.

 After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have a dditional comments.  Unless we note
otherwise, our references to prior comments are to comments in our March 21, 2016 letter.

Prospectus Summary, page 1

1. We are unable to agree with your response to prior comment 5 given the tests appear to
be in order to  pursue regulatory clearance for your system rather than for marketing.
Please revise your disclosure to highlight the limited nature of certain of the referenced
studies and trials.

Business, page 26

2. Please tell us why you do include in this section disclosure required by Item 101(a) of
Regulation S -K regarding your relationship with Electroblate, Inc.

Darrin R. Uecker
Pulse Biosciences, Inc.
April 15, 2016
Page 2

 Exhibit s

3. We are unable to agree with your response to prior comment 13 given the agreement was
performed in part after you filed the registration statement on December 22, 2015.  File
as an exhibit the research and funding agreement mentioned on page 40.

Exhibit 5.1

4. The opinion that you file to satisfy your obligations under Regulation S -K Item 60 1(b)(5)
may not assume conclusions of law that are a necessary requirement of the ultimate
opinion nor may it assume any of the material facts underlying the opinion or facts that
are readily ascertainable. We note the last two sentences of the second para graph of the
exhibit that you filed.  Please file an opinion that is revised as appropriate.

You may contact David Burton at (202) 551 -3640 or Kevin Kuhar, Accounting Branch
Chief, at (202) 551 -3662  if you have questions regarding comments on the financi al statements
and related matters.  Please contact Tom Jones at (202) 551 -3602 or me at (202) 551 -3528 with
any other questions.

Sincerely,

 /s/ Amanda Ravitz

Amanda Ravitz
Assistant Director
Office of Electronics and Machinery

cc:   Andrew Hudders,  Esq.